recommended for patients with a prior allergic response to allopurinol who cannot be treated with other oral ULT agents. The level of evidence supporting this recommendation was very low Febuxostat Switching to an alternative oral ULT agent, if available and consistent with other recommendations in this guideline, is conditionally recommended for patients taking febuxostat with a history of CVD or a new CVD-related event. At the Voting Panel meeting, there was much discussion about the data,